VIR

Vir Biotechnology, Inc.

• Simply Wall St·2d ago

  Does Vir Biotechnology (VIR) Board Shuffle Hint At A Deeper Shift Toward Oncology?

• TipRanks·6d ago

  Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (CABA) and Vir Biotechnology (VIR)

• Dow Jones·6d ago

  Vir Biotechnology Price Target Raised to $21.00/Share From $20.00 by Leerink Partners

• Dow Jones·6d ago

  Vir Biotechnology Is Maintained at Outperform by Leerink Partners

• Benzinga·6d ago

  Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21

• PUBT·06/02 21:35

  Vir director Janet Napolitano disposes of 3,200 Vir Biotechnology shares for $30,240

• PUBT·06/02 21:32

  Vir Biotechnology SVP, Chief Accounting Officer Brent Sabatini sells 379 shares for $3,581.55

• TipRanks·06/01 09:22

  Barclays Sticks to Its Buy Rating for Vir Biotechnology (VIR)

• TipRanks·06/01 01:16

  Alec Stranahan Reiterates Buy on Vir Biotechnology, Sees Undervalued Pipeline with Unchanged $16 Price Target

• TipRanks·05/28 14:47

  H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)

• TipRanks·05/28 13:39

  Vir Biotechnology Announces Board Changes and Shareholder Approvals

• PUBT·05/28 13:06

  Vir Biotechnology shareholders elect three directors at annual meeting

• TipRanks·05/27 13:50

  Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), GeoVax Labs (GOVX) and Vir Biotechnology (VIR)

• Simply Wall St·05/26 07:11

  Will Phase 2 SOLSTICE Hepatitis Delta Data Shape Vir Biotechnology's (VIR) High-Risk Antiviral Strategy?

• Simply Wall St·05/25 00:20

  Assessing Vir Biotechnology (VIR) Valuation After Hepatitis Delta Data Update And Astellas Oncology Partnership